{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:00:17Z","timestamp":1793041217277,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.esmoop.2024.103959","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T15:34:49Z","timestamp":1729611289000},"page":"103959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7767-8532","authenticated-orcid":false,"given":"L.","family":"Algeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7290-8643","authenticated-orcid":false,"given":"L.","family":"Falkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-0798","authenticated-orcid":false,"given":"F.","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4265-2627","authenticated-orcid":false,"given":"S.","family":"Frassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Boselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4038-8033","authenticated-orcid":false,"given":"D.","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4400-0451","authenticated-orcid":false,"given":"M.","family":"Zanobini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Crona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0213-6538","authenticated-orcid":false,"given":"L.","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mazzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gervaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-1778","authenticated-orcid":false,"given":"M.G.","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Welin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0704","authenticated-orcid":false,"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib1","first-page":"e4322","article-title":"Incidence of neuroendocrine tumors in the United States from 2001-2015: a United States Cancer Statistics Analysis of 50 states","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103959_bib2","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J\u00a0Neuroendocrinol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103959_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103959_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000376","article-title":"Carcinoid-syndrome: recent advances, current status and controversies","volume":"25","author":"Ito","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib5","doi-asserted-by":"crossref","first-page":"e13249","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J\u00a0Neuroendocrinol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103959_bib6","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s00520-016-3189-z","article-title":"Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden","volume":"24","author":"Pearman","year":"2016","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103959_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejcts.2010.10.035","article-title":"Outcomes, risks and complications of cardiac surgery for carcinoid heart disease","volume":"40","author":"Bhattacharyya","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"issue":"Pt 6","key":"10.1016\/j.esmoop.2024.103959_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/000456320203900605","article-title":"Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease","volume":"39","author":"Carling","year":"2002","journal-title":"Ann Clin Biochem"},{"issue":"Pt 5","key":"10.1016\/j.esmoop.2024.103959_bib9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0004563215613109","article-title":"Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement","volume":"53","author":"Adaway","year":"2016","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103959_bib10","doi-asserted-by":"crossref","first-page":"e1673","DOI":"10.1210\/clinem\/dgaa924","article-title":"Plasmatic and urinary 5-hydroxyindolacetic acid measurements in patients with midgut neuroendocrine tumors: a GTE study","volume":"106","author":"de Mestier","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103959_bib11","first-page":"e220077","article-title":"The role of serotonin inhibition within the treatment of carcinoid syndrome","volume":"3","author":"George","year":"2023","journal-title":"Endocr Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103959_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103959_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/02841869309083912","article-title":"Metastatic carcinoid tumors and the malignant carcinoid syndrome","volume":"32","author":"Kvols","year":"1993","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103959_bib14","doi-asserted-by":"crossref","first-page":"e13174","DOI":"10.1111\/jne.13174","article-title":"Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome","volume":"34","author":"Koumarianou","year":"2022","journal-title":"J\u00a0Neuroendocrinol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103959_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103959_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/13651820701504199","article-title":"Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors","volume":"9","author":"Gomez","year":"2007","journal-title":"HPB (Oxford)"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib18","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","author":"Ferolla","year":"2012","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103959_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103959_bib20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103959_bib21","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2024.103959_bib22","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103959_bib23","doi-asserted-by":"crossref","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103959_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103959_bib26","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1634\/theoncologist.2018-0921","article-title":"TELEPRO: Patient-reported carcinoid syndrome symptom improvement following initiation of telotristat ethyl in the real world","volume":"24","author":"Strosberg","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103959_bib29","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","journal-title":"Ann Oncol"},{"issue":"5-6","key":"10.1016\/j.esmoop.2024.103959_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12672-015-0233-2","article-title":"Symptomatic control of neuroendocrine tumours with everolimus","volume":"6","author":"Bainbridge","year":"2015","journal-title":"Horm Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib31","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1530\/ERC-18-0495","article-title":"Management of carcinoid syndrome: a systematic review and meta-analysis","volume":"26","author":"Hofland","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12020-018-1537-0","article-title":"Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice","volume":"60","author":"Grozinsky-Glasberg","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103959_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103959_bib34","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.3390\/ijms24043610","article-title":"Carcinoid syndrome: preclinical models and future therapeutic strategies","volume":"24","author":"Vitale","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103959_bib35","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2008.05.047","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume":"102","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103959_bib36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib37","doi-asserted-by":"crossref","first-page":"e13060","DOI":"10.1111\/jne.13060","article-title":"Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force)","volume":"34","author":"Hofland","year":"2022","journal-title":"J\u00a0Neuroendocrinol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103959_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.esmoop.2024.103959_bib39","volume":"272","year":"2017"},{"key":"10.1016\/j.esmoop.2024.103959_bib40","series-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103959_bib41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1159\/000518651","article-title":"Clinical features and prognosis of patients with carcinoid syndrome and carcinoid heart disease: a retrospective multicentric study of 276 patients","volume":"112","author":"Fijalkowski","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib42","first-page":"790","article-title":"Analysis of patients with NET G1\/G2 neuroendocrine tumors of the small intestine in the course of carcinoid heart disease - a retrospective study","volume":"12","author":"Konsek-Komorowska","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib43","first-page":"405","article-title":"Carcinoid heart disease and decreased overall survival among patients with neuroendocrine tumors: a Retrospective Multicenter Latin American Cohort Study","volume":"8","author":"Uema","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103959_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jamaoncol.2017.3326","article-title":"Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival","volume":"4","author":"Daskalakis","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103959_bib45","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O\u2019Toole","year":"2000","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103959_bib46","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103959_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib48","first-page":"241","article-title":"The management of refractory carcinoid syndrome: challenges and opportunities ahead","volume":"21","author":"Cives","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103959_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Oberg","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103959_bib50","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2024.103959_bib51","doi-asserted-by":"crossref","first-page":"1353612","DOI":"10.3389\/fcvm.2024.1353612","article-title":"A\u00a0systematic review and meta-analysis of the diagnosis and surgical management of carcinoid heart disease","volume":"11","author":"Namkoong","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103959_bib52","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/cancers15061875","article-title":"The role of transthoracic echocardiography for assessment of mortality in patients with carcinoid heart disease undergoing valve replacement","volume":"15","author":"Brooke","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103959_bib53","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s11864-022-01023-6","article-title":"Current practice in carcinoid heart disease and burgeoning opportunities","volume":"23","author":"Lenneman","year":"2022","journal-title":"Curr Treat Options Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:14:13Z","timestamp":1733778853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924017290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2059702924017290"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103959","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103959"}}